Kang Suk Yun, Ryu Ho-Sung, Sunwoo Mun-Kyung, Kim Sang-Jin, Baik Jong-Sam, Park Mee-Young, Park Hyung-Eun, Kim Joong-Seok, Kwon Kyum-Yil, Koh Seong-Beom, Kim Young-Eun, Lee Mi-Kyong, Kim Jong-Min, Chung Sun Ju, Sohn Young-Ho
Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea.
Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
J Mov Disord. 2017 Sep;10(3):123-129. doi: 10.14802/jmd.17048. Epub 2017 Sep 22.
We aimed to investigate the effect of ropinirole on excessive daytime sleepiness (EDS) and depression in Parkinson's disease (PD) with a large population.
We conducted a cross-sectional observational study at nine hospitals in Korea between April 24, 2013, and April 22, 2015. We analyzed the demographic and clinical features, other medical history, history of antiparkinsonian medication within 6 months, Hoehn and Yahr stage (HY stage), Unified Parkinson's Disease Rating Scale (UPDRS) part II and III, Epworth Sleepiness Scale (ESS), and 30-item Geriatric Depression Scale (GDS-30).
Four-hundred-thirteen patients with PD (mean age: 65.2 ± 9.0 years; men: 227 patients) were analyzed. Multivariate logistic regression analysis showed that age at examination, UPDRS II, and GDS-30 were independent risk factors for EDS and that sex, UPDRS II, and ESS were independent risk factors for depression.
Our large group study did not find any significant associations of ropinirole with EDS and depression in Korean PD patients.
我们旨在通过大量人群研究罗匹尼罗对帕金森病（PD）患者日间过度嗜睡（EDS）和抑郁的影响。
我们于2013年4月24日至2015年4月22日在韩国的九家医院进行了一项横断面观察性研究。我们分析了人口统计学和临床特征、其他病史、6个月内的抗帕金森病药物治疗史、Hoehn和Yahr分期（HY分期）、统一帕金森病评定量表（UPDRS）第二部分和第三部分、爱泼华嗜睡量表（ESS）以及30项老年抑郁量表（GDS-30）。
对413例PD患者（平均年龄：65.2±9.0岁；男性：227例）进行了分析。多因素逻辑回归分析显示，检查时的年龄、UPDRS第二部分以及GDS-30是EDS的独立危险因素，而性别、UPDRS第二部分以及ESS是抑郁的独立危险因素。
我们的大型队列研究未发现罗匹尼罗与韩国PD患者的EDS和抑郁之间存在任何显著关联。
